Home / Compare / Retatrutide vs CagriSema

Retatrutide vs CagriSema

Retatrutide vs CagriSema: how they work, doses used, FDA status and trial weight loss (28.3% vs 20.4%), with sources.

RetatrutideCagriSema
Works onGIP + GLP-1 + glucagon (triple agonist)Amylin (cagrilintide) + GLP-1 (semaglutide)
How it is takenInjection, once weeklyInjection, once weekly
US statusPhase 3, not approved (filing planned early 2027)Not approved (FDA decision expected late 2026)
Highest dose12 mg weekly (highest trial dose)2.4 mg + 2.4 mg weekly (trial)
Key trialTRIUMPH-1 (phase 3)REDEFINE 1 (phase 3)
Average weight loss28.3% at 80 weeks (12 mg weekly)20.4% at 68 weeks (2.4 mg + 2.4 mg weekly)
Placebo in that trialnot stated in our source3.0%
Not a head-to-head comparison. The weight-loss numbers come from separate trials with different people, doses and lengths. A direct trial is the only way to know which works better.

How they differ

Retatrutide works on gip + glp-1 + glucagon (triple agonist); CagriSema works on amylin (cagrilintide) + glp-1 (semaglutide). Retatrutide is taken as: injection, once weekly.CagriSema is taken as: injection, once weekly.

Dose schedules and warnings: Retatrutide dosage chart ยท CagriSema dosage chart.

Questions

Is retatrutide stronger than cagrisema?
No trial has compared them directly. In separate trials, Retatrutide averaged 28.3% weight loss (TRIUMPH-1 (phase 3), 80 weeks) and CagriSema 20.4% (REDEFINE 1 (phase 3), 68 weeks). Different trials enroll different people over different lengths of time, so the numbers are not a fair head-to-head comparison.
Is retatrutide FDA-approved?
Phase 3, not approved (filing planned early 2027).
Is cagrisema FDA-approved?
Not approved (FDA decision expected late 2026).

Sources

  1. AJMC: Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1
  2. Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM 2025

Last checked 2026-11-16. How we pick and check sources: methodology.